The independent board, which includes specialists in sleep medicine and biostatistics, analyzed unblinded data from the eight-week treatment period. Participants had been randomized into groups receiving either 75mg or 150mg of TPM-enhanced cannabidiol or a placebo. Following the unanimous recommendation to proceed, the company is now focused on completing the full enrollment to finalize efficacy data.

CEO Dr. Paul Gavin noted that the trial design—specifically its stringent inclusion criteria and controls on the placebo effect—has proven effective in protecting the integrity of the study. While final results remain pending, the absence of safety concerns bolsters the commercial outlook for the CBD capsule. Avecho is positioning the treatment as a safer alternative to existing prescription sleep aids, which are often associated with next-day impairment and overdose risks.

This development strengthens the company’s hand as it pursues international licensing deals. Avecho previously secured an Australian commercial agreement with Sandoz, and the current momentum is expected to accelerate discussions for other global territories. Management plans to engage with the US Food and Drug Administration and other international regulators to map out the product's path to market.